Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naproxen + pregabalin is a combination therapy consisting of two distinct pharmaceutical agents used primarily for the management of pain, particularly neuropathic and inflammatory pain. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) enzymes, leading to decreased prostaglandin synthesis and thus reducing inflammation, pain, and fever[5]. Pregabalin is an anticonvulsant and analgesic agent that binds to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, modulating neurotransmitter release involved in pain signaling[3][6]. Preclinical studies suggest that this combination can act synergistically or additively to reverse hyperalgesia in models of inflammatory or neuropathic pain[4][8]. The combination may be considered when monotherapy with either agent does not provide sufficient relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naproxen + pregabalin.